Publication Name	World Journal of Gastroenterology
Manuscript ID	91502
Country	Greece

Received	2023-12-29 13:54
Peer-Review Started	2023-12-29 13:54
To Make the First Decision
Return for Revision	2024-01-19 00:56
Revised	2024-01-30 20:01
Second Decision	2024-03-04 02:52
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2024-03-04 04:40
Articles in Press	2024-03-04 04:40
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-03-07 06:23
Publish the Manuscript Online	2024-03-21 11:37

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19
Manuscript Source	Invited Manuscript
All Author List	Leonidas Brilakis, Eirini Theofilogiannakou and Panagis M Lykoudis
Funding Agency and Grant Number
Corresponding Author	Panagis M Lykoudis, MD, MSc, PhD, Lecturer, Division of Surgery & Interventional Science, University College London, Gower Street, London WC1E 6BT, United Kingdom. p.lykoudis@ucl.ac.uk
Key Words	Metabolic dysfunction-associated fatty liver disease; COVID-19; Liver fibrosis; Cytokine storm; Drug induced liver injury
Core Tip	The intricate intertwining of metabolic dysfunction-associated fatty liver disease (MAFLD) and coronavirus disease 2019 (COVID-19) presents a critical nexus with severe clinical outcomes. The symbiotic impact of MAFLD increasing susceptibility to severe COVID-19, and the reciprocal exacerbation by the viral infection, mandate special attention. Early identification, vigilant monitoring and tailored evidence-based interventions, navigating both conditions, are pivotal in mitigating adverse effects. Investigating the molecular pathways underlying the synergistic effects of MAFLD and COVID-19, and the impact of specific COVID-19 treatment drugs on liver function and their potential exacerbation of MAFLD, stands as a promising research avenue that could unveil novel therapeutic targets.
Publish Date	2024-03-21 11:37
Citation	Brilakis L, Theofilogiannakou E, Lykoudis PM. Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19. World J Gastroenterol 2024; 30(11): 1480-1487
URL	https://www.wjgnet.com/1007-9327/full/v30/i11/1480.htm
DOI	https://dx.doi.org/10.3748/wjg.v30.i11.1480

Full Article (PDF)	WJG-30-1480-with-cover.pdf
Manuscript File	91502_Auto_Edited-YJP.docx
Answering Reviewers	91502-Answering reviewers.pdf
Audio Core Tip	91502-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	91502-Conflict-of-interest statement.pdf
Copyright License Agreement	91502-Copyright license agreement.pdf
Peer-review Report	91502-Peer-review(s).pdf
Scientific Misconduct Check	91502-Bing-Fan JR-2.png
Scientific Editor Work List	91502-Scientific editor work list.pdf